Lapatinib
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
{| class="wikitable" border="1" width="40%" style="text-align:center" | {| class="wikitable" border="1" width="40%" style="text-align:center" | ||
|- | |- | ||
| - | ! colspan="6" align="center"| Tyrosine Kinase Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] <ref>D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.</ref> | + | ! colspan="6" align="center"| Tyrosine Kinase Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] <ref>D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.</ref><ref>R. Khosravan, et al. General Poster Session, Developmental Therapeutics: Cytotoxic Chemotherapy, J Clin Oncol 26: 2008 (May 20 suppl; abstr 2578)</ref> |
|- | |- | ||
! Parameter | ! Parameter | ||
| Line 17: | Line 17: | ||
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml) | ! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml) | ||
! 115 | ! 115 | ||
| - | ! | + | ! 24.6 |
! Sorafenib (Nexavar) | ! Sorafenib (Nexavar) | ||
|- | |- | ||
| Line 32: | Line 32: | ||
! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ||
! 9.6 | ! 9.6 | ||
| - | ! | + | ! 83 |
! Sorafenib (Nexavar) | ! Sorafenib (Nexavar) | ||
|- | |- | ||
! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ||
! 1429 | ! 1429 | ||
| - | ! | + | ! 1921 |
! Sorafenib (Nexavar) | ! Sorafenib (Nexavar) | ||
|- | |- | ||
| Line 47: | Line 47: | ||
! Dosage (mg) | ! Dosage (mg) | ||
! 100 | ! 100 | ||
| - | ! | + | ! 50 |
! Sorafenib (Nexavar) | ! Sorafenib (Nexavar) | ||
|- | |- | ||
Revision as of 08:00, 6 December 2010
Pharmacokinetics
| Tyrosine Kinase Inhibitor Pharmacokinetics [1][2] | |||||
|---|---|---|---|---|---|
| Parameter | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Tmax (hr) | 4 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Cmax (ng/ml) | 115 | 24.6 | Sorafenib (Nexavar) | ||
| Bioavailability (%) | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Protein Binding (%) | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| T1/2 (hr) | 9.6 | 83 | Sorafenib (Nexavar) | ||
| AUC (ng/ml/hr) | 1429 | 1921 | Sorafenib (Nexavar) | ||
| IC50 (nM) | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Dosage (mg) | 100 | 50 | Sorafenib (Nexavar) | ||
| Metabolism | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
